Speclipse
Know More About Speclipse
Skin cancer is one of the most visible forms of cancer, yet achieving a confirmed diagnosis still requires time, specialised expertise, and invasive procedures such as dermoscopy and biopsy. At Palmyra Medical, we utilise Spectra-Scope® to provide fast, non-invasive, and highly accurate skin cancer assessments.
This advanced system enables physicians to deliver immediate, scar-free evaluations for all major types of skin cancer. By combining detailed biochemical analysis of skin tissue through Laser-Induced Plasma Spectroscopy (LIPS) with a proprietary AI-powered diagnostic algorithm, Spectra-Scope® delivers near-instant results with exceptional sensitivity and specificity.
Developed by Speclipse, Inc., a medical device company founded by Stanford University graduates and a leading dermatologist, Spectra-Scope® represents a breakthrough in medical diagnostics. This innovative technology allows Palmyra Medical to offer reliable, evidence-based skin cancer screening without compromising accuracy—helping patients avoid unnecessary biopsies while ensuring early, confident detection.
Spectra-Scope
Detect the Invisible in an Instant
Most skin cancers become more dangerous when diagnosis is delayed. Traditional testing methods often take days or weeks to confirm results, slowing down treatment.
At Palmyra Medical, we use Spectra-Scope® to provide fast, non-invasive, and highly accurate skin cancer assessments. This portable device analyses skin tissue using Laser-Induced Plasma Spectroscopy (LIPS) and advanced AI technology, delivering near-instant results to support early detection and timely care.
Speclipse
Why Choose Speclipse?
Increase Early
Diagnosis Accuracy
Lesions that are secondarily verified by Spectra-Scope® have a higher chance of being correctly diagnosed as positive through biopsy.
Enhanced System
Efficiency & Productivity
The detailed visual examination of challenging lesions to determine diagnosis and treatment is time consuming. Spectra-Scope® can scan these lesions and provide verification in a matter of seconds without compromising clinical accuracy.
Reduced the Number
of Unnecessary Biopsy
Challenging lesions can be verified by Spectra-Scope® before being sent for biopsy, avoiding unnecessary biopsies of benign lesions.
Speclipse
AI Skin Cancer Detection
with Unmatched Accuracy
Each skin tissue emission spectrum captured using LIPS contains over 4,000 data points, providing detailed biochemical insight into the tissue. These spectral patterns vary depending on different medical conditions.
At Palmyra Medical, Spectra-Scope® uses a proprietary deep learning diagnostic algorithm to accurately distinguish between basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma. This system is powered by a deep neural network trained on more than 5,300 emission spectra, ensuring reliable and clinically validated results.